CMRX Chimerix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CMRX

Price (delayed)

$1.28

Market cap

$112.99M

P/E Ratio

0.65

Dividend/share

N/A

EPS

$1.97

Enterprise value

$88.97M

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious ...

Highlights
The net income has soared by 199% YoY and by 12% from the previous quarter
The EPS has soared by 197% YoY and by 13% from the previous quarter
CMRX's quick ratio is down by 34% since the previous quarter
The equity has declined by 6% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.chimerix.com
Peers: EBS SIGA GILD MRK

Key stats

What are the main financial stats of CMRX
Market
Shares outstanding
88.27M
Market cap
$112.99M
Enterprise value
$88.97M
Valuations
Price to earnings (P/E)
0.65
Price to book (P/B)
0.44
Price to sales (P/S)
3.31
EV/EBIT
0.52
EV/EBITDA
0.52
EV/Sales
2.63
Earnings
Revenue
$33.82M
EBIT
$172.2M
EBITDA
$172.31M
Free cash flow
-$46.94M
Per share
EPS
$1.97
Free cash flow per share
-$0.54
Book value per share
$2.92
Revenue per share
$0.39
TBVPS
$3.19
Balance sheet
Total assets
$279.34M
Total liabilities
$22.48M
Debt
$1.82M
Equity
$256.86M
Working capital
$207.72M
Liquidity
Debt to equity
0.01
Current ratio
11.18
Quick ratio
10.7
Net debt/EBITDA
-0.14
Margins
EBITDA margin
509.4%
Gross margin
98.7%
Net margin
509%
Operating margin
-178.5%
Efficiency
Return on assets
99.5%
Return on equity
113.5%
Return on invested capital
261.2%
Return on capital employed
66.5%
Return on sales
509.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CMRX stock price

How has the Chimerix stock price performed over time
Intraday
-4.48%
1 week
-5.88%
1 month
-22.42%
1 year
-75.05%
YTD
-31.18%
QTD
-31.18%

Financial performance

How have Chimerix's revenue and profit performed over time
Revenue
$33.82M
Gross profit
$33.38M
Operating income
-$60.39M
Net income
$172.17M
Gross margin
98.7%
Net margin
509%
The net income has soared by 199% YoY and by 12% from the previous quarter
The net margin has soared by 106% YoY and by 10% from the previous quarter
The company's operating margin has surged by 98% YoY and by 22% QoQ
The operating income has soared by 65% YoY and by 21% QoQ

Growth

What is Chimerix's growth rate over time

Valuation

What is Chimerix stock price valuation
P/E
0.65
P/B
0.44
P/S
3.31
EV/EBIT
0.52
EV/EBITDA
0.52
EV/Sales
2.63
The EPS has soared by 197% YoY and by 13% from the previous quarter
The stock's price to book (P/B) is 89% less than its last 4 quarters average of 4.0 and 85% less than its 5-year quarterly average of 2.9
The equity has declined by 6% since the previous quarter
CMRX's P/S is 99% lower than its last 4 quarters average of 255.6 and 97% lower than its 5-year quarterly average of 104.3
Chimerix's revenue has increased by 2.3% from the previous quarter

Efficiency

How efficient is Chimerix business performance
CMRX's return on assets has surged by 177% year-on-year but it is down by 17% since the previous quarter
Chimerix's return on equity has surged by 170% YoY but it has decreased by 23% QoQ
The ROS has soared by 106% YoY and by 9% from the previous quarter
Chimerix's ROIC has plunged by 57% from the previous quarter

Dividends

What is CMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMRX.

Financial health

How did Chimerix financials performed over time
The total assets has soared by 178% YoY but it has contracted by 4.9% from the previous quarter
CMRX's quick ratio is down by 34% since the previous quarter
The debt is 99% less than the equity
The debt to equity has shrunk by 96% YoY
The debt has plunged by 89% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.